// App-Quantinova.ai

S144 : GENETIC MARKERS AND OUTCOME IN FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX - UPDATED ANALYSIS OF THE CLL14 TRIAL

Researchers

Presenter

  • Eugen Tausch

Principal Investigators

  • Christof Schneider

  • Deyan Yosifov

  • Sandra Robrecht

  • Can Zhang

  • Othman Al-Sawaf

  • Barbara Eichhorst

  • Anna-Maria Fink

  • Johannes Bloehdorn

  • Karl-Anton Kreuzer

  • Maneesh Tandon

  • Yanwen Jiang

  • Su Young Kim

  • Michele Porro Lura

  • Hartmut Dhner

  • Kirsten Fischer

  • Michael Hallek

  • Stephan Stilgenbauer

Medical Centers

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • AbbVie, N Chicago, United States

  • Genentech Inc., San Francisco, United States

  • Department of Internal Medicine III,Ulm University Hospital,Ulm,Alemania

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, University of Cologne, Cologne, Germany

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, University of Cologne, Cologne, Germany

Locations

  • Switzerland

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Neurogenic locus notch homolog protein 1

  • B-cell lymphoma 2

  • Baculoviral IAP repeat-containing protein3

  • Exportin 1

  • Immunoglobulin heavy-chain variable region gene

  • Tumor protein p53

  • Splicing Factor 3b Subunit 1

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

  • Venetoclax

  • TP53

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved